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Abstract 
The synthesis of a variety of 1,8-substituted anthraquinones, anthrones and 
bianthrones and their potential as antifungal agents is evaluated.  Preliminary 
screening against Schizosaccharomyces pombe (S. pombe), a fission yeast, and 
Saccharomyces cerevisiae (S. cerevisiae), a budding yeast, is reported.  Both these 
yeast species demonstrate close homologue to a number of pathogenic fungi. 
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Fungal infections continue to be a serious problem for modern-day healthcare with 
incidences rising notably over the last decade, as resistance to classical antifungals 
has become more apparent.[1-3]  This is combined with the increased susceptibility of 
immunocompromised patients to infection from emerging opportunistic fungal 
strains.[4-7]  To counteract this, healthcare professionals and drug companies seek 
more aggressive forms of chemotherapeutic treatments with the azoles shown to be 
good candidates.  There is no doubt that the azoles drugs have revolutionised clinical 
mycology, by targeting the biosynthesis of ergosterol.  However, these drugs are not 
without problems including: 
1. Toxicity – Although the azoles are competitive inhibitors for fungal CYP51, 
these drugs also affect mammalian xenobiotic-metabolising CYP enzymes,[8]  
2. Resistance – The prolonged and overuse of the azoles has led to the 
emergence of resistant yeast strains.[9,10] 
With the increase in microbial resistance, there is now a clear and direct need for novel 
drug candidates to combat this worrying situation with medicinal chemists now 
focusing their attention towards the areas of semi-synthetic and natural product 
chemistry.   
The quinones, in particular the anthraquinones as shown in Figure 1, are one type of 
natural product which is well documented for having wide ranging biological properties, 
these include anti-bacterial,[11] anti-ulcer,[12] anti-cancer,[13] anti-inflammatory[14] and 
anti-viral[15] activity.  Indeed, various natural and synthetic substituted anthraquinones 
and their phenanthroperylene cousin, hypericin, have also been recorded to have 
significant antifungal activity.[16-20]   
 
 
Figure 1. Anthraquinones from Rheum emodi (Polygonaceae). 
 
Surprisingly, there is a lack of data on the antifungal activity  for the hypericin type 
intermediates, the anthones and bianthrones.  Inspired by this, we have set out to 
create a small library of structurally similar anthraquinones, anthrones and bianthrones 
and study their antifungal activity in two different yeast species; Schizosaccharomyces 
pombe (S. pombe), a fission yeast; Saccharomyces cerevisiae (S. cerevisiae), a 
budding yeast, both used extensively in eukaryotic microbiological research. These 
yeast species demonstrate close homologue to a number of pathogenic fungi. For 
example, S. cerevisiae is a yeast closely related to Candida albicans, a widespread 
commensal and important pathogen of humans, and S.pombe is closely related to 
Pneumocystis jiroveci which is a fungal infection of the lungs.[21] S. cerevisiae itself is 
also emerging as an opportunistic pathogen, especially in immunosuppressed and 
immunocompromised patients and has been associated with fungemia, endocarditis, 
peritonitis, meningitis, ventriculitis, and with polymicrobial fatal pneumonia in AIDS 
patients.[22, 23] These yeast can serve as models to learn more about pathogenic fungi, 
in particular with regard to regulatory features and drug therapy, because yeast as a 
fungal species shares many characteristics with its pathogenic relatives.[24] Therefore, 
the aforementioned yeast can be used as representative species for screening of 
chemical libraries for fungicidal activity, without exposure to fungi that are harmful to 
human health.[25] 
 
Detailed synthetic pathways to target the anthraquinones, anthrones and bianthrones 
are shown below in Schemes 1.   
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i. p-TsCl, Et3N, MeCN; ii. SnCl2, HCl, AcOH; iii. KtOBu, DMF, MW-130C; iv. KtOBu, DMF, Reflux.  
Scheme 1. Synthetic route to the anthroquinones (5a-6a), anthrones (4b-6b) and 
bianthrones (4c–6c). 
 
All compounds made within this study followed standard published methodology.   The 
mono and tosylation of 1,8-hydroxyanthroquinone 5a and 6a was accomplished using 
reported methods[30, 31] with minor modifications from 1,8-dihydroxyanthroquinone 
(4a).  The anthrones (4b–6b and 8b) were prepared by chemoselective reduction of 
the carbonyl group in the 10th position of the 1,8-substituted anthraquinones.  This 
method of chemoselective reduction has been previously demonstrated by the NOE 
interaction of the newly introduced protons at the 10th position, with the protons in 
positions 4 and 5.[32] Finally, the bianthrones (4c-6c and 8c) was formed either under 
under wet or microwave conditions using the newly reduced anthrone.[33] Scheme 2 
shows the synthesis of emodin bianthrone (8c) from the starting emodin (8a) using the 
same method as above. 
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i. SnCl2, HCl, AcOH; ii. KtOBu, DMF, MW-130C.  
Scheme 2. Synthesis of the emodin anthrone and emodin bianthrone. 
 
One of the main driving factors for the introduction of the tosyloxy functionality was to 
determine if amino substituents could be added with relative ease.  This was studied 
using the mono-protected 5a, which was independently reacted with three 1° diamines 
(ethylenediamine, trimethylenediamine or putrescine) to yield monosubstituted 
compounds 7a-c as shown in Scheme 3.  
  
 
Scheme 3. The synthetic route to the mono substituted aminoanthroquinones (7a-c). 
 
The diamines were used in a 4 molar excess; the ability to remove the tosylate groups 
being controlled by the selection of an appropriate solvent, which in this case was 
dichloromethane under reported conditions.[30]  The only variation noted using this 
procedure being the 4 molar excess of the 1° diamine in comparison to a 250 molar 
excess of the amine which had been reported.  The amine functionalities were not 
added to the anthrones (4b-6b) or bianthones (5c-6c) due to large scale reactivity and 
purification issues encountered.  
The synthesised compounds were tested in vitro to determine growth inhibitory activity 
using a standard method.[4, 36]  Minimum inhibitory concentration (MIC) values were 
i. R-NH2, DCM, Reflux, 2h
7a R = (CH2)2NH2
7b R = (CH2)3NH2 
7c R = (CH2)4NH2
5 7
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determined in sets by comparison with the following compounds, which are 
intermediates towards the natural product hypericin; emodin (8a), emodin anthrone 
(8b) and emodin bianthrone (8c).  Emodin itself is a well-known antifungal and has 
been used as a positive control for this study.  Its mechanism of action is thought to 
be due to induction of DNA damage.[34]  
 
Table 1 shown below gives the full set of antifungal data collected in this study.  The 
substituted anthraquinones, showed varied results between each of the yeast species. 
In S. pombe, they were consistently inhibitive at concentrations greater than 1000 µM 
(4a, 5a and 6a).  In S. cerevisiae, the results were varied, with emodin (8a) and 
compounds 5a and 6a having similar results to that of the S. pombe. However, the 
MIC for 4a in S. cerevisiae was twice that for S.pombe, 2910µM compared to 1460µM, 
with the unsubstituted 9,10-anthroquinone also showing similar results to 4a.     
The amine substituted anthraquinones 7a-c showed a range of activities against both 
yeast strains tested, but all MICs were lower than 900µM.  When compared against 
the control emodin (8a), 7a-c showed lower MICs, with both 7a and 7b being approx. 
3.5 times more active against the S. pombe (440µM and 420µM) and approx. 1.5 times 
more active against the S. cerevisiae (886µM and 844µM).  It’s interesting to note 7c 
showed the greatest activity of the three with the MIC being approx. 6.5 times higher 
against both yeast species (200µM), when compared to emodin (8a).  It is postulated 
that this is due to increasing the length of amine chain, which will increase the 
lipophilicity of the molecule, allowing for better membrane penetration.[35]  Finally, all 
compounds within this family were fungastatic apart from 7b and 7c which were shown 
to be fungicidal against S. pombe alone.   
The growth inhibition concentrations for the anthrones are shown alongside 8b.  It is 
interesting to note that 8b is 13 times more active against S. pombe in comparison to 
the control 8a (97.6µM versus 1300µM).  The anthones 4b, 5b and 6b (55.3µM, 
65.7µM and 46.8µM) are approx. 1.5 times more active against S. pombe when 
compared to the 8b (97.6µM ) and approx. 20 times  more active when compared to 
8a (1300µM).  It is also noteworthy that 8b (1950µM) is less active against S. 
cerevisiae by a factor of 1.5 when compared against 8a (1300µM), however, 4b 
(553µM), 5b (329µM) and 6b (234µM) again show superior activity when compared to 
both 8a and 8b respectively. However, the MICs are still significantly higher than that 
seen in S. pombe.  The unsubstituted anthrone followed the same trend as the other 
compounds but were less active against S. pombe in comparison to the other 
anthrones, whilst showing the same type of activity against S. cerevisiae as 4b.  All 
compounds within this family were shown to be fungistatic, apart from 8b that was 
fungicidal, against S. cerevisiae.          
Finally, the antifungal activity of the bianthrones show a variation in results.  8c, the 
bianthrone substited emodin, was showed to be slightly more active than 8a, the 
emodin anthraquinone, when compared against both yeast species, 980µM and 1300 
µM respectively.  Compound 4c showed to be 13 times more active against S. pombe 
(140µM) and 2 times more active against S. cerevisiae (555µM) when compared to 
the control emodin (8a) and emodin bianthrone (8c).  Compound 5c again showed 
almost identical activity against both S. pombe and S. cerevisiae, 460µM and 461µM 
respectively.  The unsubstituted bianthrone gave the lowest activity against both 
activity S. pombe and S. cerevisiae, 1355µM and 2168 µM respectively. Finally 6c, 
showed no growth inhibition at the concentrations tested. All compounds tested within 
this study, except 6c, were found to be fungistatic in both yeast species.  It should be 
noted that the cLogP data given in Table 1 shows no correlation to the activity.   
 
Anthraquinones 
  
Compound R1 R3 R6 R8 cLogP MIC (µM) 
S. pombe S/C S. cerevisiae S/C 
9,10-Anthraquinone H H H H 3.67 1250 S 2001 S 
Emodin (8a) OH OH CH3 OH 3.01 1300 S 1300 S 
4a OH H H OH 3.13 1460 S 2910 S 
5a OH H H OTs 4.77 1770 S 1770 S 
6a OTs H H OTs 6.40 1280 S 1280 S 
7a OH H H NH(CH2)2NH2 0.9 440 S 886 S 
7b OH H H NH(CH2)3NH2 1.44 420 C 844 S 
7c OH H H NH(CH2)4NH2 1.98 200 C 201 S 
Anthrones  
 
Compound R1 R3 R6 R8 cLogP  MIC (µM) 
S. pombe S/C S. cerevisiae S/C 
Anthrone H H H H 3.49 267 S 534 S 
Emodin Anthrone (8b) OH OH Me OH 3.25 97.6 S 1950 C 
4b OH H H OH 3.38 55.3 S 553 S 
5b OH H H OTs 4.80 65.7 S 329 S 
6b OTs H H OTs 6.22 46.8 S 234 S 
Bianthrones 
 
 
Compound R1&R1
a 
R3&R3
a 
R6&R6a R8& R8a cLogP MIC (µM) 
S. pombe S/C S. cerevisiae S/C 
Bianthrone H H H H 7.69 1355 S 2168 S 
Emodin Bianthrone (8c) OH OH Me OH 6.37 980 S 980 S 
4c OH H H OH 6.62 140 S 555 S 
5c OH H H OTs 9.06 460 S 461 S 
6c OTs H H OTs 9.82  -  - 
Minimal Inhibitory Growth Concentration (MIC) of synthesised compounds tested in Schizosaccharomyces pombe 
(S.pombe), Saccharomyces cerevisiae (S. cerevisiae). Cells were inoculated at a concentration of 3 x 104/ml. 
Culture media tested were in yeast extract broth (YE) for S.pombe and complex growth media (YPD) for S. 
cerevisiae. Growth of yeast was determined visually after 24 hours incubation at 30 °C. The MIC of the compounds 
were determined to be the well before yeast growth was first seen. The experiment was repeated three times to 
ensure reproducibility of the results. Compounds were determined to be fungicidal (C), if no growth was observed, 
and fungistatic (S), if normal growth was seen after inoculation into fresh media. . - Growth seen in all wells up to 
600 µM concentration. 
Table 1. Structures and growth inhibitory data for the 1,8-substituted anthroquinones.  
R = OTs = 
R = OTs = 
R = OTs = 
In conclusion, the anthraquinones (5a and 6a), anthrones (4b-6b and 8b) and 
bianthrones (4c-6c and 8c) were all prepared using literature methods in varying yields 
from pre-purchased compounds (4a and 8a).  The synthesis of the monoamino 
substituted anthraquinones (7a-c) was also successfully accomplished using literature 
methods with minor modifications.  The target anthraquinones, anthrones and 
bianthrones are important from a structural viewpoint; the toluenesulphonyl 
functionality allows easy addition of amino functionalities, this has the advantage of 
greater intrinsic water solubility and allows for further attachments to take place such 
as amino acids, mono-clonal antibodies etc.  This would be advantageous as it would 
be a route to specific cell targeting.  Preliminary screen of all the compounds in this 
study showed varying levels of antifungal activity, with the control emodin, often 
showing poorer activity when compared to the other compounds in this study.  As 
highlighted earlier in this study, the mechanism of action of emodin (8a) is thought to 
be due to induction of DNA damage.[34] However, the compounds shown in this study 
are fungistatic, thus suggesting an alternative mode of action is highly plausible  
It should also be noted that there is no correlation between cLogP data given in Table 
1 and compound activity, which might suggest the growth inhibition is not the result of 
an intracellular mechanism of action.  It is clear from these results that the anthrones 
(4b-6b), the bianthrones (4c-5c) and the amino substituted anthraquinones (7a-c) 
show promising antifungal activity and should form the structural basis towards 
possible new antifungal leads.   
 
Notes 
The authors declare no competing financial interest. 
 
Acknowledgement 
The authors would like to thank the Faculty of Science and Technology at the 
University of Central Lancashire for financially supporting this study. 
  
References 
 
1. Wiederhold, NP. The antifungal arsenal: alternative drugs and future targets, 
International Journal of Antimicrobial Agents. 2018;51:333-339.  
2. Ostrosky-Zeichner L, Casadevall A, Galgiani JN, Odds FC, Rex JH. An insight 
into the antifungal pipeline: selected new molecules and beyond, Nat. Rev. 
Drug Discovery. 2010;9:719-727. 
3. Campoy S, Adrio JL. Antifungals, Biochemical Pharmacology. 2017;133:86-96. 
4. Tyler AR, Okoh AO, Lawrence CL, Jones VC, Moffatt C, Smith RB. N-Alkylated 
2,3,3-trimethylindolenines and 2-methylbenzothiazoles. Potential lead 
compounds in the fight against Saccharomyces cerevisiae infections, European 
Journal of Medicinal Chemistry. 2013;64:222-227. 
5. Kung HC, Huang PY, Chen WT, Ko BS, Chen YS, Chang SC, Chuang YC, 
2016 Guidelines for the use of antifungal agents in patients with invasive fungal 
diseases in Taiwan, Journal of Microbiology. Immunology and Infection. 
2018;51:1-176.   
6. Puia-Dumitrescu M, Smith PB, Antifungal Drugs in Newborns and Children, 
Pediatric Clinics of North America. 2017;64:1389-1402. 
7. Ajmal S, Mahmood M, Saleh OA, Larson J, Sohail MR. Invasive fungal 
infections associated with prior respiratory viral infections in 
immunocompromised hosts, Infection. 2018;46:555-558. 
8. Mortimer CG, Wells G, Crochard JP, Stone EL, Bradshaw TD, Stevens MFG, 
Westwell AD, Antitumor Benzo thiazoles. 26.1 2-(3,4-Dimethoxyphenyl)-5-
fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-
Arylbenzothiazole, Shows Potent and Selective Inhibitory Activity against Lung, 
Colon, and Breast Cancer Cell Lines, J. Med. Chem. 2006;49:179-185. 
9. Berger S, El Chazli Y, Babu A.F, Coste AT, Azole Resistance in Aspergillus 
fumigatus: A Consequence of Antifungal Use in Agriculture?, Front Microbiol. 
2017;8:1024. 
10. Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal drug resistance: 
evolution, mechanisms and impact, Current Opinion in Microbiology. 
2018;45:70-76. 
11. Zhang J, Redman N, Litke AP, Zeng J, Zhan J, Chan KY, Chang CW. Synthesis 
and antibacterial activity study of a novel class of cationic anthraquinone 
analogs, Bioorg Med Chem. 2011;19:498-503. 
12. Ayo RG. Phytochemical constituents and bioactivities of the extracts of Cassia 
nigricans Vahl, Journal of Medicinal Plants Research. 2010;4:1339-1348. 
13. Cichewicz RH, Zhang Y, Seeram NP, Nair MG. Inhibition of human tumor cell 
proliferation by novel anthraquinones from day lilies, Life Sci. 2004;74:1791-
1799. 
14. Prati F, Bartolini M, Simoni E, Angela De Simone A, Pinto A, Andrisano V, 
Bolognesi ML. Quinones bearing non-steroidal anti-inflammatory fragments as 
multitarget ligands for Alzheimer’s disease, Bioorg Med Chem Lett. 
2013;23:6254-6258. 
15. Zhou M, Xing HH, Yang Y, Wang YD, Zhou K, Dong W, Li GP, Hu WY, Liu Q,  
Li XM, Hu QF. Three new anthraquinones from the twigs of Cassia fistula and 
their bioactivities, Journal of Asian Natural Products Research. 2017;19:1073–
1078. 
16. Milošević T, Solujić S, Antimicrobial Activity of the HypercumPerforatum L. 
Plant, Bulletin of the Chemists and Technologists of Macedonia. 2006;25:127–
130.  
17. Abubakar EMM, Antibacterial activity of crude extracts of Euphorbia hirta 
against some bacteria associated with enteric infections, Journal of Medicinal 
Plants Research. 2009;3:498-505.   
18. Saddiqe Z, Naeem I, Maimoona A. A review of the antibacterial activity of 
Hypericum perforatum L, Journal of Ethnopharmacology. 2010;131:511-552. 
19. Singh DN, Verma N, Raghuwanshi S, Shuklaband PK, Kulshreshth DK. 
Antifungal anthraquinones from Saprosma fragrans, Bioorg Med Chem Lett. 
2006;16:4512–4514. 
20. Arif T, Bhosale JD, Kumar N, Mandal TK, Bendre RS, Lavekar GS. Dabur R. 
Natural products – antifungal agents derived from plants, Journal of Asian 
Natural Products Research. 2009;11:621-638 
21. Anderson JB, Sirjusingh C, Parsons AB, Boone C, Wickens C, Cowen LE, Kohn 
LM, Mode of Selection and Experimental Evolution of Antifungal Drug 
Resistance in Saccharomyces cerevisiae, Genetics. 2003;163:1287-1298. 
22.  Marcet-Houben M, Gabaldón T. The tree versus the forest: the fungal tree of 
life and the topological diversity within the yeast phylome, PLoS One. 2009;4 
1-8. 
23. Skovgaard N. New trends in emerging pathogens, International Journal of Food 
Microbiology, 2007;120:217–224.  
24. Hazen KC. New and emerging yeast pathogens. Clinical Microbiology Reviews. 
1995;8:462–478. 
25. Goldstein AL, McCusker JH, Development of Saccharomyces cerevisiae as a 
model pathogen. A system for the genetic identification of gene products 
required for survival in the mammalian host environment, Genetics. 2001;159: 
499-513.   
26. Lawrence CL, Maekawa H, Worthington JL, Reiter W, Wilkinson CRM, Jones 
N, Regulation of Schizosaccharomyces pombe Atf1 protein levels by Sty1-
mediated phosphorylation and heterodimerization with Pcr1, J Biol Chem. 
2007;282:5160-5170. 
27. Moreno S, Klar A, Nurse P. Molecular genetic analysis of fission yeast 
Schizosaccharomyces pombe, Methods Enzymol. 1991;194:795-823. 
28. Brachmann CB, Davies A, Cost GJ, Caputo E, Li J, Hieter P, Boeke JD. 
Designer deletion strains derived from Saccharomyces cerevisiae S288C: a 
useful set of strains and plasmids for PCR-mediated gene disruption and other 
applications, Yeast. 1998;14:115-132. 
29. Treco DA, Lundblad V, Preparation of Yeast Media, In Current Protocols in 
Molecular Biology. John Wiley & Sons, Inc.: 2001. 
30. Zielske AG. (Tosyloxy)anthraquinones. Versatile synthons for the preparation 
of various aminoanthraquinones, J. Org. Chem. 1987;52,1305–1309. 
31. Sangthong S, Ha H, Teerawattananon T, Ngamrojanavanich N, Neamati N, 
Muangsin N. Overcoming doxorubicin-resistance in the NCI/ADR-RES model 
cancer cell line by novel anthracene-9,10-dione derivatives, Bioorg Med Chem 
Lett. 2013;23:6156-6160. 
32. Motoyoshiya J, Masue Y, Nishii Y, Aoyama H. Synthesis of Hypericin via 
Emodin Anthrone Derived from a Two-fold Diels-Alder Reaction of 1,4-
Benzoquinone, Natural Product Communications. 2007;2:67-70. 
33. Aigner S, Falk H. A microwave-assisted synthesis of phenanthroperylene 
quinones as exemplified with hypericin, Monatsh Chem. 2008;139:991–993. 
34. Sharma R, Tiku AB, Giri A. Pharmacological Properties of Emodin – 
Anthraquinone Derivatives, Journal of Natural Products and Resources. 
2017;3:97–101  
35. Haraguchi H, Kataoka S, Okamoto S, Hanafi M, Shibata K. Antimicrobial 
Triterpenes from Ilex integra and the mechanism of antifungal action, Phytother. 
Res.1999;13:151-156. 
36. The growth inhibitory activity of the compounds were determined by screening 
S. pombe and S.cerevisiae using the following method: Yeast species were 
inoculated into relevant media; S. pombe (NJ2 h- ura4-D18 leu1-32 ade6-M210 
his7-366)[26] into yeast extract broth (YE),[27] and S.cerevisiae (strain BY4741a, 
a derivative of S288C, (MATahis3 1 leu2 0 met15 0ura3 0)[28] into complex 
media (YPD).[29]  The culture was then incubated for 12 hours at 30oC with 
shaking at 200 rpm. Stock solutions of the compounds were prepared in 20% 
(v/v) DMSO and culture media. DMSO and culture media were used as controls 
for the experiment. 3 x 104 exponential growing yeast cells were transferred 
into the wells of a 96-well plate. A 1:2 serial dilution of the compounds was then 
performed. The wells were inspected visually for growth of yeast after 24 hours 
of incubation at 30 °C. Growth was indicated by full or partial white appearance 
of yeast on the bottom of the wells. The MIC values of the compounds were 
determined to be the well before yeast growth was first seen. The experiment 
was repeated three times to ensure reproducibility of the results.  To determine 
whether compounds had fungistatic or fungicidal activity, cells were taken from 
the well on the microtitre plate at the concentration where lack of yeast growth 
was first observed. These cells were inoculated into fresh culture media, to 
strongly dilute the presence of the compound, and grown for 24 hours at 30oC 
with shaking at 200rpm. Compounds were determined to be fungicidal, if no 
growth was observed, and fungistatic, if normal growth was seen.     
